Subunit vaccine efficacy against Botulinum neurotoxin subtypes

Area of Science:

• Immunology
• Microbiology
• Vaccinology

Background:

• Botulinum neurotoxins (BoNT) are classified into seven serotypes (A-G).
• Recombinant subunit vaccines, including those using the highly-conserved receptor binding domain (HCR), are being developed.
• BoNT serotypes exhibit genetic variants (subtypes) with significant amino acid variations.

Purpose of the Study:

• To evaluate the protective efficacy of the HCR of BoNT/A against challenge by heterologous BoNT/A subtypes.
• To characterize the immune responses elicited by HCR/A subunit vaccines.

Main Methods:

• Mice were vaccinated with high or low doses of HCR/A subtypes (A1-A4).
• Vaccinated mice were challenged with heterologous BoNT/A subtypes (A1-A3).
• Serum IgG titers against HCRs and specific sub-domains were measured.

Main Results:

• High-dose HCR/A vaccination conferred protection against heterologous BoNT/A subtype challenge.
• Low-dose HCR/A vaccination provided partial protection and induced subtype-specific IgG responses.
• Antibody responses to native and denatured HCR sub-domains correlated with protection.

Conclusions:

• HCR/A subunit vaccines demonstrate potential for cross-protection against BoNT/A subtypes.
• Low-dose vaccination strategies may elicit distinct neutralizing antibody profiles.
• Findings support the development of broadly protective BoNT vaccines.